

Ulf Andersson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7332061/publications.pdf>

Version: 2024-02-01

129
papers

22,609
citations

21215

62
h-index

18400

124
g-index

139
all docs

139
docs citations

139
times ranked

18757
citing authors

#	ARTICLE	IF	CITATIONS
1	HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation. <i>Blood</i> , 2022, 139, 3181-3193.	0.6	23
2	HMGB1 is a critical molecule in the pathogenesis of Gram-negative sepsis. <i>Journal of Intensive Medicine</i> , 2022, 2, 156-166.	0.8	6
3	Famotidine exerts anti-inflammatory effects via a vagus nerve-dependent mechanism. <i>FASEB Journal</i> , 2022, 36, .	0.2	1
4	Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm. <i>Molecular Medicine</i> , 2022, 28, 57.	1.9	13
5	Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome—Hemophagocytic Lymphohistiocytosis. <i>Journal of Rheumatology</i> , 2021, 48, 1596-1602.	1.0	26
6	Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. <i>Immunity</i> , 2021, 54, 454-467.e6.	6.6	74
7	Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome. <i>Molecular Medicine</i> , 2021, 27, 48.	1.9	7
8	Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 2717-2722.	0.7	17
9	Redox modifications of cysteine residues regulate the cytokine activity of HMGB1. <i>Molecular Medicine</i> , 2021, 27, 58.	1.9	25
10	HMGB1 released from nociceptors mediates inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	34
11	Neurons Are a Primary Driver of Inflammation via Release of HMGB1. <i>Cells</i> , 2021, 10, 2791.	1.8	13
12	Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation. <i>Cells</i> , 2021, 10, 3323.	1.8	32
13	Identification of a brainstem locus that inhibits tumor necrosis factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29803-29810.	3.3	76
14	Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. <i>Molecular Medicine</i> , 2020, 26, 42.	1.9	176
15	The cholinergic anti-inflammatory pathway alleviates acute lung injury. <i>Molecular Medicine</i> , 2020, 26, 64.	1.9	43
16	Prolonged elevation of plasma HMGB1 is associated with cognitive impairment in intensive care unit survivors. <i>Intensive Care Medicine</i> , 2020, 46, 811-812.	3.9	11
17	Expression of Concern to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). <i>Molecular Medicine</i> , 2020, 26, 18.	1.9	3
18	Targeting Inflammation Driven by HMGB1. <i>Frontiers in Immunology</i> , 2020, 11, 484.	2.2	320

#	ARTICLE	IF	CITATIONS
19	Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. <i>Molecular Medicine</i> , 2020, 26, 17.	1.9	0
20	Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. <i>Molecular Medicine</i> , 2019, 25, 13.	1.9	75
21	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2019, 16, 45.	3.1	21
22	Biphasic Release of the Alarmin High Mobility Group Box 1 Protein Early After Trauma Predicts Poor Clinical Outcome. <i>Critical Care Medicine</i> , 2019, 47, e614-e622.	0.4	11
23	Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms. <i>Journal of Innate Immunity</i> , 2018, 10, 215-227.	1.8	41
24	Extracellular HMGB1 as a therapeutic target in inflammatory diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 263-277.	1.5	225
25	Identification of ethyl pyruvate as a NLRP3 inflammasome inhibitor that preserves mitochondrial integrity. <i>Molecular Medicine</i> , 2018, 24, 8.	1.9	29
26	High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. <i>Seminars in Immunology</i> , 2018, 38, 40-48.	2.7	221
27	Adenylyl Cyclase 6 Mediates Inhibition of TNF in the Inflammatory Reflex. <i>Frontiers in Immunology</i> , 2018, 9, 2648.	2.2	49
28	Immunization Elicits Antigen-Specific Antibody Sequestration in Dorsal Root Ganglia Sensory Neurons. <i>Frontiers in Immunology</i> , 2018, 9, 638.	2.2	15
29	Expression of Concern: The haptoglobin beta subunit sequesters <sc>HMGB</sc>1 toxicity in sterile and infectious inflammation. <i>Journal of Internal Medicine</i> , 2017, 282, 76-93.	2.7	33
30	Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice. <i>Molecular Medicine</i> , 2016, 22, 585-596.	1.9	5
31	Systemic HMGB1 Neutralization Prevents Postoperative Neurocognitive Dysfunction in Aged Rats. <i>Frontiers in Immunology</i> , 2016, 7, 441.	2.2	81
32	C1q and HMGB1 reciprocally regulate human macrophage polarization. <i>Blood</i> , 2016, 128, 2218-2228.	0.6	130
33	A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. <i>Hepatology</i> , 2016, 64, 1699-1710.	3.6	96
34	Blood pressure regulation by CD4+ lymphocytes expressing choline acetyltransferase. <i>Nature Biotechnology</i> , 2016, 34, 1066-1071.	9.4	74
35	TLR4-dependant pro-inflammatory effects of HMGB1 on human adipocyte. <i>Adipocyte</i> , 2016, 5, 384-388.	1.3	21
36	Characterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 605-619.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Regulation of Posttranslational Modifications of HMGB1 During Immune Responses. Antioxidants and Redox Signaling, 2016, 24, 620-634.	2.5	98
38	Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight, 2016, 1, .	2.3	112
39	HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors. Molecular Medicine, 2015, 21, 951-958.	1.9	45
40	High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Molecular Medicine, 2015, 21, S6-S12.	1.9	275
41	MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. Journal of Experimental Medicine, 2015, 212, 5-14.	4.2	295
42	High Systemic Levels of the Cytokine-Inducing HMGB1 Isoform Secreted in Severe Macrophage Activation Syndrome. Molecular Medicine, 2014, 20, 538-547.	1.9	45
43	Î±7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation by Preventing Mitochondrial DNA Release. Molecular Medicine, 2014, 20, 350-358.	1.9	169
44	Expression of Concern: The functions of HMGB1 depend on molecular localization and posttranslational modifications. Journal of Internal Medicine, 2014, 276, 420-424.	2.7	80
45	JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3068-3073.	3.3	300
46	Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain, 2014, 155, 1802-1813.	2.0	141
47	A Systematic Nomenclature for the Redox States of High Mobility Group Box (HMGB) Proteins. Molecular Medicine, 2014, 20, 135-137.	1.9	94
48	Expression of Concern: HMGB1 mediates splenomegaly and expansion of splenic CD11b+ L ^o C ^{high} inflammatory monocytes in murine sepsis survivors. Journal of Internal Medicine, 2013, 274, 381-390.	2.7	74
49	TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Annals of the Rheumatic Diseases, 2013, 72, 1390-1399.	0.5	81
50	The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of Leukocyte Biology, 2013, 93, 865-873.	1.5	449
51	Regulation of HMGB1 release by inflammasomes. Protein and Cell, 2013, 4, 163-167.	4.8	144
52	TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO Journal, 2013, 32, 172-172.	3.5	2
53	High Mobility Group Box Protein 1 (HMGB1)-Partner Molecule Complexes Enhance Cytokine Production by Signaling Through the Partner Molecule Receptor. Molecular Medicine, 2012, 18, 224-230.	1.9	92
54	HMGB1-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Annals of the Rheumatic Diseases, 2012, 71, A80.1-A80.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1). <i>Molecular Medicine</i> , 2012, 18, 250-259.	1.9	378
56	HMGB1 mediates muscle fatigue via TLR4 - a possible mechanism for muscle fatigue in patients with inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A42.2-A43.	0.5	0
57	Neural reflexes in inflammation and immunity. <i>Journal of Experimental Medicine</i> , 2012, 209, 1057-1068.	4.2	308
58	Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. <i>Journal of Experimental Medicine</i> , 2012, 209, 1519-1528.	4.2	590
59	HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. <i>Nature Reviews Rheumatology</i> , 2012, 8, 195-202.	3.5	596
60	Pro-Inflammatory Cytokines Produced by Growth Plate Chondrocytes May Act Locally to Modulate Longitudinal Bone Growth. <i>Hormone Research in Paediatrics</i> , 2012, 77, 180-187.	0.8	18
61	TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. <i>EMBO Journal</i> , 2012, 32, 86-99.	3.5	117
62	Reflex Principles of Immunological Homeostasis. <i>Annual Review of Immunology</i> , 2012, 30, 313-335.	9.5	348
63	Novel role of PKR in inflammasome activation and HMGB1 release. <i>Nature</i> , 2012, 488, 670-674.	13.7	672
64	Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. <i>Journal of General Physiology</i> , 2012, 140, i3-i3.	0.9	0
65	A new approach to rheumatoid arthritis: treating inflammation with computerized nerve stimulation. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2012, 2012, 3.	0.1	8
66	HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection. <i>Annual Review of Immunology</i> , 2011, 29, 139-162.	9.5	1,230
67	Successful therapy with anti-HMGB1 monoclonal antibodies in two separate experimental arthritis models. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A77-A78.	0.5	0
68	Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit. <i>Science</i> , 2011, 334, 98-101.	6.0	1,158
69	High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. <i>Arthritis Research and Therapy</i> , 2011, 13, R136.	1.6	117
70	Monoclonal Anti-HMGB1 (High Mobility Group Box Chromosomal Protein 1) Antibody Protection in Two Experimental Arthritis Models. <i>Molecular Medicine</i> , 2011, 17, 1039-1044.	1.9	101
71	Molecular basis of applied biological therapeutics. <i>Journal of Internal Medicine</i> , 2011, 269, 2-7.	2.7	4
72	Introduction: HMGB1 in inflammation and innate immunity. <i>Journal of Internal Medicine</i> , 2011, 270, 296-300.	2.7	44

#	ARTICLE	IF	CITATIONS
73	Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. <i>Arthritis and Rheumatism</i> , 2010, 62, 2963-2972.	6.7	49
74	Immunomodulatory Drugs Regulate HMGB1 Release from Activated Human Monocytes. <i>Molecular Medicine</i> , 2010, 16, 343-351.	1.9	40
75	Immunomodulatory drugs can inhibit the extracellular release of HMGB1 from cultured human monocytes. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A36-A37.	0.5	0
76	Interleukin 1 α and TLR ligands give enhanced cytokine production by their interaction with HMGB1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A38-A38.	0.5	0
77	Effects of HMGB1 on <i>in vitro</i> responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. <i>FASEB Journal</i> , 2010, 24, 570-578.	0.2	74
78	A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11942-11947.	3.3	705
79	The role of HMGB1 in the pathogenesis of rheumatic disease. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2010, 1799, 141-148.	0.9	104
80	Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1602-1607.	3.3	113
81	The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. <i>Journal of Leukocyte Biology</i> , 2009, 86, 655-662.	1.5	263
82	High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. <i>Immunobiology</i> , 2009, 214, 303-309.	0.8	57
83	A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. <i>Biomarkers</i> , 2009, 14, 572-586.	0.9	51
84	High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. <i>Arthritis Research and Therapy</i> , 2008, 10, 209.	1.6	164
85	Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients – a prospective clinical study. <i>Arthritis Research and Therapy</i> , 2008, 10, R33.	1.6	34
86	Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. <i>Arthritis Research and Therapy</i> , 2008, 10, R1.	1.6	37
87	Pivotal Advance: Inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. <i>Journal of Leukocyte Biology</i> , 2008, 83, 31-38.	1.5	45
88	HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. <i>Journal of Leukocyte Biology</i> , 2007, 81, 129-136.	1.5	39
89	Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1656-1660.	0.5	20
90	Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2007, 9, R35.	1.6	36

#	ARTICLE	IF	CITATIONS
91	Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2007, 56, 674-687.	6.7	58
92	Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. <i>Arthritis and Rheumatism</i> , 2005, 52, 3880-3889.	6.7	79
93	Title is missing!. <i>Arthritis Research</i> , 2005, 7, P85.	2.0	1
94	Reversing established sepsis with antagonists of endogenous high-mobility group box 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 296-301.	3.3	1,085
95	HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. <i>Journal of Internal Medicine</i> , 2004, 255, 318-319.	2.7	31
96	Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. <i>Arthritis and Rheumatism</i> , 2004, 50, 1586-1594.	6.7	102
97	Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. <i>European Journal of Immunology</i> , 2004, 34, 1503-1512.	1.6	379
98	HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 627-637.	0.8	49
99	Tumor Necrosis Factor, Interleukin 11, and Leukemia Inhibitory Factor Produced by Langerhans Cells in Langerhans Cell Histiocytosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 706-711.	0.3	29
100	High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 876-881.	6.7	82
101	High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1693-1700.	6.7	161
102	HMGB1 in Sepsis. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 577-584.	1.5	97
103	Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1. <i>Molecular Medicine</i> , 2003, 9, 37-45.	1.9	295
104	Structural basis for the proinflammatory cytokine activity of high mobility group box 1. <i>Molecular Medicine</i> , 2003, 9, 37-45.	1.9	148
105	High Mobility Group Box Chromosomal Protein 1 (HMGB1) Is an Antibacterial Factor Produced by the Human Adenoid. <i>Pediatric Research</i> , 2002, 52, 148-154.	1.1	55
106	High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2598-2603.	6.7	261
107	HMGB1 as a DNA-binding cytokine. <i>Journal of Leukocyte Biology</i> , 2002, 72, 1084-91.	1.5	215
108	Dynamics of Early Synovial Cytokine Expression in Rodent Collagen-Induced Arthritis. <i>American Journal of Pathology</i> , 2001, 158, 491-500.	1.9	39

#	ARTICLE	IF	CITATIONS
109	Systemic anti-tumor necrosis factor $\hat{\pm}$ therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor $\hat{\pm}$ synthesis. <i>Arthritis and Rheumatism</i> , 2000, 43, 2391-2396.	6.7	154
110	High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes. <i>Journal of Experimental Medicine</i> , 2000, 192, 565-570.	4.2	1,306
111	Identification of Rat IL-1 $\hat{\pm}$, IL-2, IFN- $\hat{\pm}$ and TNF- $\hat{\pm}$ in Activated Splenocytes by Intracellular Immunostaining. <i>Biotechnic and Histochemistry</i> , 2000, 75, 101-109.	0.7	10
112	HMG-1 as a Late Mediator of Endotoxin Lethality in Mice. <i>Science</i> , 1999, 285, 248-251.	6.0	3,807
113	Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 1997, 40, 865-874.	6.7	246
114	Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-Guerin. <i>Journal of Urology</i> , 1996, 156, 536-541.	0.2	44
115	Computerized assessment of production of multiple human cytokines at the single-cell level using image analysis. <i>Journal of Leukocyte Biology</i> , 1996, 59, 287-295.	1.5	47
116	Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. <i>European Journal of Immunology</i> , 1996, 26, 1-9.	1.6	68
117	Dissociation between cytokine mRNA expression and protein production in shigellosis. <i>European Journal of Immunology</i> , 1996, 26, 1130-1138.	1.6	35
118	The Production of Immunoregulatory Cytokines is Localized to the Extrafollicular Area of Human Tonsils. <i>Acta Oto-Laryngologica</i> , 1996, 116, 477-485.	0.3	32
119	Upregulated Local Cytokine Production in Recurrent Tonsillitis Compared with Tonsillar Hypertrophy. <i>Acta Oto-Laryngologica</i> , 1995, 115, 689-696.	0.3	34
120	Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes. <i>Immunological Reviews</i> , 1994, 139, 21-42.	2.8	156
121	Serological Follow-up after Treatment of Borrelia Arthritis and Acrodermatitis Chronica Atrophicans. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 339-347.	1.5	20
122	Strategies of Anti-Cytokine Monoclonal Antibody Development: Immunoassay of IL-10 and IL-5 in Clinical Samples. <i>Immunological Reviews</i> , 1992, 127, 5-24.	2.8	365
123	Bacterial Toxin-Induced Cytokine Production Studied at the Single-Cell Level. <i>Immunological Reviews</i> , 1992, 127, 69-96.	2.8	173
124	Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. <i>European Journal of Immunology</i> , 1992, 22, 2617-2623.	1.6	112
125	Assessment of Cytokines by Immunofluorescence and the Paraformaldehyde-Saponin Procedure. <i>Immunological Reviews</i> , 1991, 119, 65-93.	2.8	462
126	Simultaneous production of interleukin 2, interleukin 4 and interferon- $\hat{\pm}$ by activated human blood lymphocytes. <i>European Journal of Immunology</i> , 1990, 20, 1591-1596.	1.6	167

#	ARTICLE	IF	CITATIONS
127	Identification of individual tumor necrosis factor/ cachectin-producing cells after lipopolysaccharide induction. European Journal of Immunology, 1988, 18, 983-988.	1.6	52
128	Gamma-Interferon is Produced by CD3+ and CD3- Lymphocytes. Immunological Reviews, 1987, 97, 51-65.	2.8	63
129	Phenotypic characterization of individual interferon- γ -producing cells after OKT3 antibody activation. European Journal of Immunology, 1986, 16, 1457-1460.	1.6	16